When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AIM - AIM ImmunoTech/Roswell Park initiates enrollment in combo trial in COVID-19 patients with cancer
AIM ImmunoTech Inc.
AIM ImmunoTech (NYSEMKT:AIM)begins recruitment in Roswell Park Comprehensive Cancer Center's Phase 1/2a clinical study of the effectiveness of rintatolimod (Ampligen) in combination with interferon alpha-2b in treating cancer patients with mild or moderate COVID-19.
More news on: AIM ImmunoTech Inc., Healthcare stocks news,